APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Disease CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neurodegenerative Disease CDMO Market Outlook and Growth Opportunities 2026

16 April 2026Not stated

Choose your research edition.

Industry ResearchNeurodegenerative Disease CDMO Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Disease CDMO Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Disease CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Disease CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Disease CDMO Market Analysis and Forecast 2026-2032258 pages · $4,950 USD

Market perspective

The global Neurodegenerative Disease CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neurodegenerative Disease CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurodegenerative Disease CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurodegenerative Disease CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neurodegenerative Disease CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neurodegenerative Disease CDMO market include AC Immune, Alterity Therapeutics, Biogen, Charles River Laboratories, Coave Therapeutics, Sysmex Corp, Donanemab, Eisai and Fujirebio Holdings, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Neurodegenerative Disease CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurodegenerative Disease CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurodegenerative Disease CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neurodegenerative Disease CDMO market.

Neurodegenerative Disease CDMO Segment by Company

AC Immune

Alterity Therapeutics

Biogen

Charles River Laboratories

Coave Therapeutics

Sysmex Corp

Donanemab

Eisai

Fujirebio Holdings

GenSight Biologics

Neuropore Therapies

Nevrargenics

PPD

Samsung Biologics

Sanofi(Vigil Neuroscience)

Neurodegenerative Disease CDMO Segment by Type

Small Molecule Drug CDMO

Biopharmaceutical CDMO

Cell and Gene Therapy (CGT) CDMO

OtherS

Neurodegenerative Disease CDMO Segment by Application

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple System Atrophy (MSA)

Progressive Supranuclear Palsy (PSP)

Others

Neurodegenerative Disease CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neurodegenerative Disease CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neurodegenerative Disease CDMO key companies, revenue, market share, and recent developments.

3. To split the Neurodegenerative Disease CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neurodegenerative Disease CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurodegenerative Disease CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Neurodegenerative Disease CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurodegenerative Disease CDMO industry.

Chapter 3: Detailed analysis of Neurodegenerative Disease CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neurodegenerative Disease CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neurodegenerative Disease CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurodegenerative Disease CDMO Industry Trends Table 2. Neurodegenerative Disease CDMO Industry Drivers Table 3. Neurodegenerative Disease CDMO Industry Opportunities and Challenges Table 4. Neurodegenerative Disease CDMO Industry Restraints Table 5. Global Neurodegenerative Disease CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurodegenerative Disease CDMO Revenue Share by Company (2021-2026) Table 7. Global Neurodegenerative Disease CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neurodegenerative Disease CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Neurodegenerative Disease CDMO Company, Product Type & Application Table 10. Global Neurodegenerative Disease CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neurodegenerative Disease CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Small Molecule Drug CDMO Table 15. Significant Companies of Biopharmaceutical CDMO Table 16. Significant Companies of Cell and Gene Therapy (CGT) CDMO Table 17. Significant Companies of OtherS Table 18. Global Neurodegenerative Disease CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Neurodegenerative Disease CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Neurodegenerative Disease CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Neurodegenerative Disease CDMO Sales Value Share by Type (2021-2026) Table 22. Global Neurodegenerative Disease CDMO Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Alzheimer's Disease Table 24. Significant Companies of Parkinson's Disease Table 25. Significant Companies of Huntington's Disease Table 26. Significant Companies of Amyotrophic Lateral Sclerosis (ALS) Table 27. Significant Companies of Multiple System Atrophy (MSA) Table 28. Significant Companies of Progressive Supranuclear Palsy (PSP) Table 29. Significant Companies of Others Table 30. Global Neurodegenerative Disease CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Neurodegenerative Disease CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global Neurodegenerative Disease CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global Neurodegenerative Disease CDMO Sales Value Share by Application (2021-2026) Table 34. Global Neurodegenerative Disease CDMO Sales Value Share by Application (2027-2032) Table 35. Global Neurodegenerative Disease CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Neurodegenerative Disease CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global Neurodegenerative Disease CDMO Sales Value Share by Region (2021-2026) Table 38. Global Neurodegenerative Disease CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global Neurodegenerative Disease CDMO Sales Value Share by Region (2027-2032) Table 40. Global Neurodegenerative Disease CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Neurodegenerative Disease CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global Neurodegenerative Disease CDMO Sales Value Market Share by Country (2021-2026) Table 43. Global Neurodegenerative Disease CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global Neurodegenerative Disease CDMO Sales Value Market Share by Country (2027-2032) Table 45. AC Immune Company Information Table 46. AC Immune Business Overview Table 47. AC Immune Neurodegenerative Disease CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. AC Immune Neurodegenerative Disease CDMO Product Portfolio Table 49. AC Immune Recent Development Table 50. Alterity Therapeutics Company Information Table 51. Alterity Therapeutics Business Overview Table 52. Alterity Therapeutics Neurodegenerative Disease CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Alterity Therapeutics Neurodegenerative Disease CDMO Product Portfolio Table 54. Alterity Therapeutics Recent Development Table 55. Biogen Company Information Table 56. Biogen Business Overview Table 57. Biogen Neurodegenerative Disease CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Biogen Neurodegenerative Disease CDMO Product Portfolio Table 59. Biogen Recent Development Table 60. Charles River Laboratories Company Information Table 61. Charles River Laboratories Business Overview Table 62. Charles River Laboratories Neurodegenerative Disease CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Charles River Laboratories Neurodegenerative Disease CDMO Product Portfolio Table 64. Charles River Laboratories Recent Development Table 65. Coave Therapeutics Company Information Table 66. Coave Therapeutics Business Overview Table 67. Coave Therapeutics Neurodegenerative Disease CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Coave Therapeutics Neurodegenerative Disease CDMO Product Portfolio Table 69. Coave Therapeutics Recent Development Table 70. Sysmex Corp Company Information Table 71. Sysmex Corp Business Overview Table 72. Sysmex Corp Neurodegenerative Disease CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sysmex Corp Neurodegenerative Disease CDMO Product Portfolio Table 74. Sysmex Corp Recent Development Table 75. Donanemab Company Information Table 76. Donanemab Business Overview Table 77. Donanemab Neurodegenerative Disease CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Donanemab Neurodegenerative Disease CDMO Product Portfolio Table 79. Donanemab Recent Development Table 80. Eisai Company Information Table 81. Eisai Business Overview Table 82. Eisai Neurodegenerative Disease CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Eisai Neurodegenerative Disease CDMO Product Portfolio Table 84. Eisai Recent Development Table 85. Fujirebio Holdings Company Information Table 86. Fujirebio Holdings Business Overview Table 87. Fujirebio Holdings Neurodegenerative Disease CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Fujirebio Holdings Neurodegenerative Disease CDMO Product Portfolio Table 89. Fujirebio Holdings Recent Development Table 90. GenSight Biologics Company Information Table 91. GenSight Biologics Business Overview Table 92. GenSight Biologics Neurodegenerative Disease CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. GenSight Biologics Neurodegenerative Disease CDMO Product Portfolio Table 94. GenSight Biologics Recent Development Table 95. Neuropore Therapies Company Information Table 96. Neuropore Therapies Business Overview Table 97. Neuropore Therapies Neurodegenerative Disease CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Neuropore Therapies Neurodegenerative Disease CDMO Product Portfolio Table 99. Neuropore Therapies Recent Development Table 100. Nevrargenics Company Information Table 101. Nevrargenics Business Overview Table 102. Nevrargenics Neurodegenerative Disease CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Nevrargenics Neurodegenerative Disease CDMO Product Portfolio Table 104. Nevrargenics Recent Development Table 105. PPD Company Information Table 106. PPD Business Overview Table 107. PPD Neurodegenerative Disease CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. PPD Neurodegenerative Disease CDMO Product Portfolio Table 109. PPD Recent Development Table 110. Samsung Biologics Company Information Table 111. Samsung Biologics Business Overview Table 112. Samsung Biologics Neurodegenerative Disease CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Samsung Biologics Neurodegenerative Disease CDMO Product Portfolio Table 114. Samsung Biologics Recent Development Table 115. Sanofi(Vigil Neuroscience) Company Information Table 116. Sanofi(Vigil Neuroscience) Business Overview Table 117. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Portfolio Table 119. Sanofi(Vigil Neuroscience) Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Neurodegenerative Disease CDMO Product Image Figure 2. Global Neurodegenerative Disease CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurodegenerative Disease CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurodegenerative Disease CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Small Molecule Drug CDMO Image Figure 8. Biopharmaceutical CDMO Image Figure 9. Cell and Gene Therapy (CGT) CDMO Image Figure 10. OtherS Image Figure 11. Global Neurodegenerative Disease CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Neurodegenerative Disease CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Neurodegenerative Disease CDMO Sales Value Share by Type (2021-2032) Figure 14. Alzheimer's Disease Image Figure 15. Parkinson's Disease Image Figure 16. Huntington's Disease Image Figure 17. Amyotrophic Lateral Sclerosis (ALS) Image Figure 18. Multiple System Atrophy (MSA) Image Figure 19. Progressive Supranuclear Palsy (PSP) Image Figure 20. Others Image Figure 21. Global Neurodegenerative Disease CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Neurodegenerative Disease CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Neurodegenerative Disease CDMO Sales Value Share by Application (2021-2032) Figure 24. Global Neurodegenerative Disease CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global Neurodegenerative Disease CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America Neurodegenerative Disease CDMO Sales Value (2021-2032) & (US$ Million) Figure 27. North America Neurodegenerative Disease CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe Neurodegenerative Disease CDMO Sales Value (2021-2032) & (US$ Million) Figure 29. Europe Neurodegenerative Disease CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific Neurodegenerative Disease CDMO Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific Neurodegenerative Disease CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America Neurodegenerative Disease CDMO Sales Value (2021-2032) & (US$ Million) Figure 33. South America Neurodegenerative Disease CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa Neurodegenerative Disease CDMO Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa Neurodegenerative Disease CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule Drug CDMO
  • Biopharmaceutical CDMO
  • Cell and Gene Therapy (CGT) CDMO
  • OtherS
Applications
  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple System Atrophy (MSA)
  • Progressive Supranuclear Palsy (PSP)
  • Others
Companies covered
  • AC Immune
  • Alterity Therapeutics
  • Biogen
  • Charles River Laboratories
  • Coave Therapeutics
  • Sysmex Corp
  • Donanemab
  • Eisai
  • Fujirebio Holdings
  • GenSight Biologics
  • Neuropore Therapies
  • Nevrargenics
  • PPD
  • Samsung Biologics
  • Sanofi(Vigil Neuroscience)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neurodegenerative Disease CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neurodegenerative Disease CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neurodegenerative Disease CDMO Market Dynamics
  1. 2.1 Neurodegenerative Disease CDMO Industry Trends
  2. 2.2 Neurodegenerative Disease CDMO Industry Drivers
  3. 2.3 Neurodegenerative Disease CDMO Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Disease CDMO Industry Restraints
3 Neurodegenerative Disease CDMO Market by Company
  1. 3.1 Global Neurodegenerative Disease CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Neurodegenerative Disease CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Neurodegenerative Disease CDMO Company Ranking (2024-2026)
  4. 3.4 Global Neurodegenerative Disease CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Neurodegenerative Disease CDMO Company Product Type and Application
  6. 3.6 Global Neurodegenerative Disease CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neurodegenerative Disease CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neurodegenerative Disease CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neurodegenerative Disease CDMO Market by Type
  1. 4.1 Neurodegenerative Disease CDMO Type Introduction
  2. 4.1.1 Small Molecule Drug CDMO
  3. 4.1.2 Biopharmaceutical CDMO
  4. 4.1.3 Cell and Gene Therapy (CGT) CDMO
  5. 4.1.4 OtherS
  6. 4.2 Global Neurodegenerative Disease CDMO Sales Value by Type
  7. 4.2.1 Global Neurodegenerative Disease CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Neurodegenerative Disease CDMO Sales Value by Type (2021-2032)
  9. 4.2.3 Global Neurodegenerative Disease CDMO Sales Value Share by Type (2021-2032)
5 Neurodegenerative Disease CDMO Market by Application
  1. 5.1 Neurodegenerative Disease CDMO Application Introduction
  2. 5.1.1 Alzheimer's Disease
  3. 5.1.2 Parkinson's Disease
  4. 5.1.3 Huntington's Disease
  5. 5.1.4 Amyotrophic Lateral Sclerosis (ALS)
  6. 5.1.5 Multiple System Atrophy (MSA)
  7. 5.1.6 Progressive Supranuclear Palsy (PSP)
  8. 5.1.7 Others
  9. 5.2 Global Neurodegenerative Disease CDMO Sales Value by Application
  10. 5.2.1 Global Neurodegenerative Disease CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Neurodegenerative Disease CDMO Sales Value by Application (2021-2032)
  12. 5.2.3 Global Neurodegenerative Disease CDMO Sales Value Share by Application (2021-2032)
6 Neurodegenerative Disease CDMO Regional Value Analysis
  1. 6.1 Global Neurodegenerative Disease CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurodegenerative Disease CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neurodegenerative Disease CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neurodegenerative Disease CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neurodegenerative Disease CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Neurodegenerative Disease CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neurodegenerative Disease CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Neurodegenerative Disease CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neurodegenerative Disease CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neurodegenerative Disease CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neurodegenerative Disease CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Neurodegenerative Disease CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neurodegenerative Disease CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neurodegenerative Disease CDMO Sales Value Share by Country, 2025 VS 2032
7 Neurodegenerative Disease CDMO Country-level Value Analysis
  1. 7.1 Global Neurodegenerative Disease CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurodegenerative Disease CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neurodegenerative Disease CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neurodegenerative Disease CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neurodegenerative Disease CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neurodegenerative Disease CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neurodegenerative Disease CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AC Immune
  2. 8.1.1 AC Immune Company Information
  3. 8.1.2 AC Immune Business Overview
  4. 8.1.3 AC Immune Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AC Immune Neurodegenerative Disease CDMO Product Portfolio
  6. 8.1.5 AC Immune Recent Developments
  7. 8.2 Alterity Therapeutics
  8. 8.2.1 Alterity Therapeutics Company Information
  9. 8.2.2 Alterity Therapeutics Business Overview
  10. 8.2.3 Alterity Therapeutics Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Alterity Therapeutics Neurodegenerative Disease CDMO Product Portfolio
  12. 8.2.5 Alterity Therapeutics Recent Developments
  13. 8.3 Biogen
  14. 8.3.1 Biogen Company Information
  15. 8.3.2 Biogen Business Overview
  16. 8.3.3 Biogen Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biogen Neurodegenerative Disease CDMO Product Portfolio
  18. 8.3.5 Biogen Recent Developments
  19. 8.4 Charles River Laboratories
  20. 8.4.1 Charles River Laboratories Company Information
  21. 8.4.2 Charles River Laboratories Business Overview
  22. 8.4.3 Charles River Laboratories Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Charles River Laboratories Neurodegenerative Disease CDMO Product Portfolio
  24. 8.4.5 Charles River Laboratories Recent Developments
  25. 8.5 Coave Therapeutics
  26. 8.5.1 Coave Therapeutics Company Information
  27. 8.5.2 Coave Therapeutics Business Overview
  28. 8.5.3 Coave Therapeutics Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Coave Therapeutics Neurodegenerative Disease CDMO Product Portfolio
  30. 8.5.5 Coave Therapeutics Recent Developments
  31. 8.6 Sysmex Corp
  32. 8.6.1 Sysmex Corp Company Information
  33. 8.6.2 Sysmex Corp Business Overview
  34. 8.6.3 Sysmex Corp Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sysmex Corp Neurodegenerative Disease CDMO Product Portfolio
  36. 8.6.5 Sysmex Corp Recent Developments
  37. 8.7 Donanemab
  38. 8.7.1 Donanemab Company Information
  39. 8.7.2 Donanemab Business Overview
  40. 8.7.3 Donanemab Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Donanemab Neurodegenerative Disease CDMO Product Portfolio
  42. 8.7.5 Donanemab Recent Developments
  43. 8.8 Eisai
  44. 8.8.1 Eisai Company Information
  45. 8.8.2 Eisai Business Overview
  46. 8.8.3 Eisai Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eisai Neurodegenerative Disease CDMO Product Portfolio
  48. 8.8.5 Eisai Recent Developments
  49. 8.9 Fujirebio Holdings
  50. 8.9.1 Fujirebio Holdings Company Information
  51. 8.9.2 Fujirebio Holdings Business Overview
  52. 8.9.3 Fujirebio Holdings Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Fujirebio Holdings Neurodegenerative Disease CDMO Product Portfolio
  54. 8.9.5 Fujirebio Holdings Recent Developments
  55. 8.10 GenSight Biologics
  56. 8.10.1 GenSight Biologics Company Information
  57. 8.10.2 GenSight Biologics Business Overview
  58. 8.10.3 GenSight Biologics Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GenSight Biologics Neurodegenerative Disease CDMO Product Portfolio
  60. 8.10.5 GenSight Biologics Recent Developments
  61. 8.11 Neuropore Therapies
  62. 8.11.1 Neuropore Therapies Company Information
  63. 8.11.2 Neuropore Therapies Business Overview
  64. 8.11.3 Neuropore Therapies Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Neuropore Therapies Neurodegenerative Disease CDMO Product Portfolio
  66. 8.11.5 Neuropore Therapies Recent Developments
  67. 8.12 Nevrargenics
  68. 8.12.1 Nevrargenics Company Information
  69. 8.12.2 Nevrargenics Business Overview
  70. 8.12.3 Nevrargenics Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Nevrargenics Neurodegenerative Disease CDMO Product Portfolio
  72. 8.12.5 Nevrargenics Recent Developments
  73. 8.13 PPD
  74. 8.13.1 PPD Company Information
  75. 8.13.2 PPD Business Overview
  76. 8.13.3 PPD Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 PPD Neurodegenerative Disease CDMO Product Portfolio
  78. 8.13.5 PPD Recent Developments
  79. 8.14 Samsung Biologics
  80. 8.14.1 Samsung Biologics Company Information
  81. 8.14.2 Samsung Biologics Business Overview
  82. 8.14.3 Samsung Biologics Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Samsung Biologics Neurodegenerative Disease CDMO Product Portfolio
  84. 8.14.5 Samsung Biologics Recent Developments
  85. 8.15 Sanofi(Vigil Neuroscience)
  86. 8.15.1 Sanofi(Vigil Neuroscience) Company Information
  87. 8.15.2 Sanofi(Vigil Neuroscience) Business Overview
  88. 8.15.3 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Portfolio
  90. 8.15.5 Sanofi(Vigil Neuroscience) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst